Early cancer drug trial halted after single patient
NCT ID NCT06338657
Summary
This early-phase study aimed to understand how a new packaging method for an existing chemotherapy drug (paclitaxel) affects immune cells within head and neck cancer tumors. The goal was to gather knowledge to help design future treatments, not to directly treat patients in this trial. The study was terminated after enrolling only one participant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.